首页> 外文期刊>Cancer prevention research. >Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression
【24h】

Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression

机译:动物模型中化学预防剂的筛选:结果对给定阶级的再现性,药剂和肿瘤进展期间测试的药剂

获取原文
获取原文并翻译 | 示例
       

摘要

Because of the importance of testing reproducibility of results, we present our findings regarding screening agents in preclinical chemoprevention studies in rodent models performed by the Chemopreventive Agent Development Research Group (CADRG) of the Division of Cancer Prevention of the NCI. These studies were performed via contracts to various commercial and academic laboratories. Primarily, results with positive agents are reported because positive agents may progress to the clinics. In testing reproducibility, a limited number of direct repeats of our standard screening assays were performed; which entailed initiating treatment shortly after carcinogen administration or in young transgenic mice and continuing treatment until the end of the study. However, three additional proto-cols were employed relating to reproducibility: (i) testing agents at lower doses to determine efficacy and reduced toxicity; (ii) testing agents later in tumor progression when microscopic lesions existed and, (iii) testing multiple agents of the same mechanistic class. Data with six models that were routinely employed are presented: MNU-induced ER-positive mammary cancer in rats; MMTV-Neu ER-negative mammary cancers in transgenic mice; AOM-induced colon tumors in rats; intestinal adenomas in Min mice; OH-BBN-induced invasive rat urinary bladder cancers in rats; and UV-induced skin squamous carcinomas in mice. It was found that strongly positive results were highly reproducible in the preclinical models evaluated. (C) 2018 AACR.
机译:由于测试结果的再现性的重要性,我们在癌症预防癌症预防癌症划分划分的化学预防剂开发研究组(CADRG)中的啮齿机模型中的临床前化学普化研究中的筛选剂研究结果。这些研究是通过对各种商业和学术实验室的合同进行的。主要是,报告阳性药物的结果,因为阳性药物可能对诊所进行。在测试再现性中,进行了有限数量的我们的标准筛选测定的重复;在致癌物给药后不久或在幼儿小鼠和继续治疗直至研究结束后,这需要短暂的治疗。然而,采用与再现性的三种另外的原型COL:(i)低剂量测试剂以确定疗效和降低毒性; (ii)当存在微观病变时肿瘤进展的测试剂,(iii)测试同一机制阶级的多个试剂。均常用的六种模型的数据如下:MNU诱导大鼠的ER阳性乳腺癌;在转基因小鼠中MMTV-NEU ER阴性乳腺癌;大鼠的Aom诱导的结肠肿瘤;肠道腺瘤在min小鼠中; OH-BBN诱导的大鼠侵袭性大鼠膀胱癌癌;和紫外线诱导的小鼠皮肤鳞癌。发现在评估的临床前模型中,强烈阳性结果在高度可重复。 (c)2018年AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号